ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
摘要
This article deals with current issues of pharmacotherapy of cardiovascular diseases which are based on disfunction of the renin-angiotensin-aldosterone system. As compared with the efficacy and safety of two major classes of drugs for the pharmacotherapy of cardiovascular diseases — angiotensin II receptor blockers and ACE inhibitors — are given data from clinical trials of both classes of drugs.
关于作者
K. Ghyamdzhyan
First MSMU named after I.M. Sechenov
俄罗斯联邦
俄罗斯联邦
M. Maksimov
First MSMU named after I.M. Sechenov
俄罗斯联邦
俄罗斯联邦
参考
1. Davis J.O. The second Volhard Lecture: the use of blocking agents to define the functions of the renin-angiotensin system // Clin. Sc. Mol. Med. Suppl. — 1975. — Vol. 2. — P. 3–14.
2. Gavras H., Brunner H.R., Turini G.A. et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man // N. Engl. J. Med. — 1978. — Vol. 298(18). — P. 991–995.
3. Dzau V.J. Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patients outcomes: part I: Pathophysiology and clinical trila evidence (risk factors through stable coronary artery disease) // Circulation. — 2006. — Vol. 114(25). — P. 2850–2870.
4. Агеев Ф.Т., Арутюнов Г.П., Беленков Ю.Н. Хроническая сердечная недостаточность. — М.: ГЕОТАР-Медиа, 2010.
5. Скворцов А.А., Мареев В.Ю., Беленков Ю.Н. Место блокаторов рецепторов ангиотензина II в лечении больных ХСН // Сердце. — 2008. — № 5. — 275–283.
6. Беленков Ю.Н. Мареев В.Ю. Агеев Ф.Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. — М.: ГЕОТАР-Медиа, 2006.
7. Кобалава Ж.Д., Шаварова Е.К. Антагонисты рецепторов к ангиотензину II в кардиологической практике: современный взгляд на проблему // РМЖ. — 2008. — № 11.
8. Остроумова О.Д., Максимов М.Л., Щукина Г.Н., Шорикова Е.Г. Антагонисты рецепторов к ангиотензину II в 2010: что нового? // Системные гипертензии. — № 1. — 2011.
9. Максимов М.Л., Дралова О.В., Стародубцев А.К. Антагонисты АТ1-рецепторов ангиотензина II, ингибиторы ангиотензин-превращающего фермента в регуляции гемодинамики и активности ренин-ангиотензин-альдостероновой системы. Фокус на органопротективные эффекты // Кардиоваскулярная терапия и профилактика. — 2010. — № 9(2). — С. 115–124.
10. Кобалава Ж.Д., Котовская Ю.В., Моисеев В.С. Артериальная гипертензия. Ключи к диагностике. — M.: ГЕОТАР-Медиа, 2009.
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian Survival Study (CONSENSUS) // N. Engl. J. Med. — 1987. — Vol. 316. — P. 1429–1435.
12. Lindholm L.H., Ibsen H., Dahlof B. et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol // Lancet. — 2002. — Vol. 359(9311). — P. 1004–1010.
13. Mochizuki S., Dahlof B., Taniguchi I. et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, openlabel, blinded endpoint morbidity-mortality study. — Lancet, 2007. — Vol. 369. — P. 1431–1439.
14. Parving H.H., Lenhert H. et al. The effects of irbesartan on the development of diabetic nephropathy in patients with types 2 diabetes // N. Engl. J. Med. — 2001. — Vol. 345(12). — P. 870-878.
15. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. — 2001. — Vol. 345. — P. 851–860.
16. Viberti G., Wheeldom N.M. Microalbuminuria reduction with Valsartan (MARVAL) study investigators. Microalbuminuria reduction with valsartan in patients with type II diabetes mellitus: a blood pressure-independent effect // Circulation. — 2002. — Vol. 106(6). — P. 672–678.
17. Brenner B.M., Cooper M.E., Zeeuw de D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2001. — Vol. 345(12). — P. 851–860.
18. Schrader J. et al. Morbidity and mortality after stroke, Eprosartan compared with Nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) // Stroke. — 2005. — Vol. 36(2). — P. 1218–1226.
19. Julius S., Kjeldsen S.E., Weber M. et al. Outcome in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial // Lancet. — 2004. — Vol. 363(9426). — P. 2022–2031.
20. The navigator study group. effect of Valsartan on the incidence of diabetes and cardiovascular events // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1477–1490.
21. Hollenberg N.K. et al. The Diovan reduction of Proteinuria drop study: albuminuria response to high doses of Valsartan in type 2 diabetes mellitus // Circulation. — 2006. — Vol. 114. — P. 11–61.
22. Национальные рекомендации по диагностике и лечению артериальной гипертензии ВНОК. — 4-й пересмотр, 2010 г.
23. Pitt B., Poole-Wilson P.A., Segal R. et al. Effect of Losartan compared to Captopril on mortality in patients with symptomatic heart failure; randomized trial. — Lancet. — 2000. — Vol. 355(9215). — P. 1582–1587.
24. Dickstein K., Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. — Lancet. — 2002. — Vol. 360(9335). — P. 752–760.
25. Pfeffer M.A. et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // N. Engl. J. Med. — 2003. — Vol. 349. — P. 1893–1906.
26. Cohn J.N., Tognoni G. Valsartan heart failure trial investigator. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. — 2001. — Vol. 345(23). — P. 1667–1675.
27. Granger C.B., McMurray J.V. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial // The Lancet. — 2003. — Vol. 362. — P. 772–776.
28. Baker W.L., Coleman C.I. et al. Systematic review: comparative effectiveness of Angiotensin-converting enzyme inhibitors or Angiotensin II-Receptor Blockers for ischemic heart disease // Ann. Intern. Med. — 2009. — Vol. 151. — P. 861–871.
29. Matchar D.B., McCory D.C. et al Systematic review: comparative effectiveness of Angiotensin-converting enzyme inhibitors and Angiotensin II Receptor Blockers for treating essential hypertension // Ann. Intern. Med. — 2008. — Vol. 148. — P. 16–29.
30. Kunz R., Friedrich C. et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the Renin-Angiotensin system on Proteinuria in renal disease // Ann. Intern. Med. — 2008. — Vol. 148. — P. 30–48.
31. Yusuf S., Teo K.K., Pogue J. et al. ONTARGET Investigators. Telmisartan, Ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. — 2008. — Vol. 358(15). — P. 1547–1559.
32. Wang L., Huang X.-S. et al. Effects of angiotensin blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study // J. First Mil. Med. Univ. — 2005. — Vol. 25(8).
评论
浏览:
369
Email this article 